BCM
INO icon

Brookstone Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

Brookstone Capital Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,549
Closed -$59K – 792
2022
Q1 		$59K Buy
+1,549
New +$69.8K ﹤0.01% 760

Other funds holding INO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Brookstone Capital Management's INO Position: Q2 2022 in Review

Brookstone Capital Management sold out of Inovio Pharmaceuticals (INO) in Q2 2022, closing a stake of 1,549 shares — an estimated $59K sold.

Brookstone Capital Management first reported a position in INO in Q1 2022 and held it in 1 quarter. The position peaked at $59K in Q1 2022. 184 funds tracked by Wall St. Rank hold INO as of Q2 2022.

  • Brookstone Capital Management reported no remaining Inovio Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Brookstone Capital Management sold 1,549 Inovio Pharmaceuticals shares in Q2 2022, an estimated $59K.
  • Brookstone Capital Management first reported a position in Inovio Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Brookstone Capital Management's Inovio Pharmaceuticals position peaked at $59K in Q1 2022.
  • 184 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2022.

Based on Brookstone Capital Management's 13F filing for Q2 2022, filed 11 Jul 2022.